In STAT's "jealousy list" for 2024, STAT staffers explain what makes a selection of stories they read in other publications ...

A $42,000 grant from NASA and INBRE will further CF research, through a collaborative effort spanning to India and the United Kingdom.

The Food and Drug Administration (FDA) has approved Alyftrek ™ (vanzacaftor/tezacaftor/deutivacaftor) for the treatment of cystic fibrosis (CF) in patients aged 6 years and olde ...

Allison Angell, the first person in the UK to have all of her major organs transplanted, has died aged 46—more than a decade ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a global leader in cystic fibrosis (CF) treatments. CF is a genetic ...

Changing Futures, a nonprofit dedicated to advancing cystic fibrosis (CF) research, will hold a polar plunge at noon New Year ...

Vertex Pharmaceuticals Inc. notched two FDA victories late Friday for its cystic fibrosis medicines, increasing the number of ...

Alyftrek is approved as a new treatment for cystic fibrosis, while the FDA expanded the label for Trikafta to include additional genetic mutations.

The new combination, dubbed Alyftrek, is designed to improve on the Trikafta, a product that generated sales of $8.9 billion ...

As Vertex Pharmaceuticals reels from a painful trial readout for its pain candidate suzetrigine, the Boston biotech has ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Vertex Pharmaceuticals Inc.’s chief operating officer Stuart Arbuckle said during the Stifel Healthcare Conference in November that his firm’s launch last year of Casgevy (exagamglogene autotemcel) ...